The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Perry Gregory D since 2011.
The trader's CIK number is 1236371.
At the time of the last reporting, Perry Gregory D was the Chief Financial Officer of Novelion Therapeutics Inc.. (stock ticker symbol NVLNF).
Also see all insider trading activities at Novelion Therapeutics Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2017 | NVLN | 0 | $0 | 0 | $0 | 2,393 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2013 | IMGN | 0 | $0 | 18,337 | $326,691 | 18,337 | $79,215 |
2011 | IMGN | 0 | $0 | 49,998 | $626,880 | 49,998 | $215,988 |
1. Novelion Therapeutics Inc. (NVLN)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2017-05-09 | NVLN | Option Ex | 2,393 | .00 | 0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2013-09-10 | IMGN | Option Ex | 18,337 | 4.32 | 79,215 |
2013-09-10 | IMGN | Sale | 18,337 | 17.82 | 326,691 |
2011-11-15 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-11-15 | IMGN | Sale | 8,333 | 12.58 | 104,862 |
2011-10-17 | IMGN | Sale | 8,333 | 13.40 | 111,645 |
2011-10-17 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-09-26 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-09-26 | IMGN | Sale | 8,333 | 11.00 | 91,663 |
2011-08-15 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-08-15 | IMGN | Sale | 8,333 | 11.05 | 92,121 |
2011-07-15 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-07-15 | IMGN | Sale | 8,333 | 15.12 | 126,019 |
2011-06-29 | IMGN | Option Ex | 8,333 | 4.32 | 35,998 |
2011-06-29 | IMGN | Sale | 8,333 | 12.07 | 100,570 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Perry Gregory D (Chief Financial Officer of Novelion Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.